Primärtherapie bei Patientinnen mit Mammakarzinom: Evidenz, Kontroversen, Konsens

Zusammenfassung

Die alle 2 Jahre stattfindende internationale Konsensuskonferenz in St. Gallen zur Behandlung von Patientinnen mit primärem Mammakarzinom wurde dieses Jahr zum 14. Mal veranstaltet und fand aus logistischen Gründen erstmals nicht in St. Gallen (Schweiz), sondern unter gleichem Namen in Wien (Österreich) statt. Da sich das internationale Panel in St. Gallen aus Experten unterschiedlicher Länder zusammensetzt, spiegelt der Konsensus ein internationales Meinungsbild wider. Aus deutscher Sicht erscheint es daher sinnvoll, die Abstimmungsergebnisse vor dem Hintergrund der aktualisierten Therapieempfehlungen der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-Mamma 2015) für den Therapiealltag in Deutschland zu konkretisieren. Eine deutsche Arbeitsgruppe aus 14 Brustkrebsexperten, von denen 3 Mitglieder des internationalen St.-Gallen-Panels sind, hat daher die Abstimmungsergebnisse der St.-Gallen-Konsensuskonferenz 2015 für den Klinikalltag in Deutschland zeitnah kommentiert. Inhaltliche Schwerpunkte der 14. St.-Gallen-Konferenz waren erneut operative Fragestellungen der Brust und der Axilla, radioonkologische und systemische Therapieoptionen des primären Mammakarzinoms unter Berücksichtigung der Tumorbiologie sowie der klinische Einsatz von Multigen-Assays. Ein Fokus lag zudem auf der Behandlung älterer und jüngerer Patientinnen, inkl. spezieller Situationen wie die Diagnostik/Behandlung eines Mammakarzinoms in und nach einer Schwangerschaft sowie den Erhalt der Fertilität.

Abstract

For the first time, this yearʼs St. Gallen International Consensus Conference on the treatment of patients with primary breast cancer, which takes place every two years, was held not in St. Gallen (Switzerland) but – for logistical reasons – in Vienna (Austria) under its usual name. The 2015 St. Gallen International Consensus Conference was the 14th of its kind. As the international panel of the St. Gallen conference consists of experts from different countries, the consensus mirrors an international cross-section of opinions. From a German perspective, it was considered useful to translate the results of the votes of the St. Gallen conference into practical suggestions, particularly in light of the recently updated treatment guideline of the Gynecologic Oncology Group (AGO-Mamma 2015) in Germany. A German group consisting of 14 breast cancer experts, three of whom are members of the international St. Gallen panel, has therefore provided comments on the results of this yearʼs votes at the 2015 St. Gallen Consensus Conference and their impact on clinical care in Germany. The 14th St. Gallen conference once again focused on surgery of the breast and the axilla, radio-oncologic and systemic treatment options for primary breast cancer depending on tumor biology, and the clinical use of multigene assays. The conference also considered targeted therapies for older and for younger patients, including such special circumstances as the diagnosis/treatment of breast cancer during and after pregnancy and the preservation of fertility.

Schlüsselwörter

Mammakarzinom - St.-Gallen-Konsensus - adjuvante Therapie - neoadjuvante Therapie - Multigensignaturen

Key words

breast cancer - St. Gallen consensus - adjuvant therapy - neoadjuvant therapy - multigene signatures

^* St. Gallen Panel Expert

• Literatur

• 1 Coates AS, Winer EP, Goldhirsch A et al. Tailoring therapies – improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 2015; DOI: 10.1093/annonc/mdv221.
• 2 Online: http://www.ago-online.de vom 08.04.2015; Stand: 30.04.2015
• 3 Boughey JC, Suman VJ, Mittendorf EA et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 2013; 310: 1455-1461
• 4 Kühn T, Bauerfeind I, Fehm T et al. Sentinel-lymph-node biopsy with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective multi-center cohort study. Lancet Oncol 2013; 14: 609-618
• 5 Boughey JC, Ballman KV, Symmans WF et al. Methods impacting the false negative rate of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0 – T4,N1 – 2) who receive neoadjuvant chemotherapy – Results from a prospective trial – ACOSOG Z1071 (Alliance). SABCS 2014; P2-01-02
• 6 Giuliano AE, McCall L, Beitsch P et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010; 252: 426-432
• 7 Online: http://www.astro.org vom 19.03.2015; Stand: 30.04.2015
• 8 Online: http://www.estro.org (2012); Stand: 30.04.2015
• 9 Smith BD, Arthur DW, Buchholz TA et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys 2009; 74: 987-1001
• 10 Polgár C, Van Limbergen E, Pötter R et al. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). Radiother Oncol 2010; 94: 264-273
• 11 Poortmans P, Struikmans H, Kirkove C et al. Irradiation of the internal mammary and medical supraclavicular lymph nodes in stage I to III breast cancer: 10 years results of the EORTC Radiation Oncology and Breast Cancer Groups phase III trial 22922/10925. ECCO 2013, Amsterdam, Presidential Session, LBA 2
• 12 Denkert C, von Minckwitz G, Brase JC et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol 2015; 33: 983-991
• 13 Francis PA, Regan MM, Fleming GF et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2015; 372: 436-446
• 14 Gnant M, Mlineritsch B, Stoeger H et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol 2015; 26: 313-320
• 15 Cuzick J, Sestak J, Baum M et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10 year analysis of the ATAC trial. Lancet Oncol 2010; 11: 1135-1141
• 16 Regan MM, Neven P, Giobbie-Hurder A et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1–98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol 2011; 12: 1101-1108
• 17 Burstein HJ, Temin S, Anderson H et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol 2014; 32: 2255-2269
• 18 Nitz U, Gluz O, Kates RE et al. Prognostic impact of discordance between different risk assessment tools in early breast cancer: Early outcome analysis from the prospective phase III WSG-PlanB trial. SABCS 2014; P4-11-01
• 19 Wolff AC, Hammond ME, Hicks DG et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guidelines update. J Clin Oncol 2013; 31: 3997-4013
• 20 Untch M, Jackisch C, Schneeweiss A et al. A randomized phase III trial comparing neoadjuvant chemotherapy with weekly nanoparticle-based paclitaxel with solventbased paclitaxel followed by anthracycline/cyclophosphamide for patients with early breast cancer (GeparSepto); GBG 69. SABCS 2014; S2–07
• 21 Sikov WM, Berry DA, Perou CM et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 2015; 33: 13-21
• 22 von Minckwitz G, Schneeweiss A, Loibl S et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 2014; 15: 747-756
• 23 Ando M. Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/Epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression. Breast Cancer Res Treat 2014; 145: 401-409
• 24 Coleman R, Gnant M, Paterson A et al. Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer. A meta-analysis of individual patient data from randomized trials. SABCS 2013; S4-07